All In Biotech

Drug Trial Radar · NCT03212404

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers

A Phase 1, Open-label, Multicenter, Dose-escalation Study of CK-301 Administered Intravenously as a Single Agent to Subjects With Advanced Cancers

Last checked: Nov 20, 2026Latest source record: Feb 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

272

Actual

Start

Sep 20, 2017

Primary completion

Nov 18, 2021

Study completion Dec 2025

Sponsor

Lead sponsor
Checkpoint Therapeutics, Inc.Industry
Sponsor type
Industry
Collaborators
Novotech (Australia) Pty Limited
First posted
Jul 11, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

CK-301 (cosibelimab) is a fully human monoclonal antibody of IgG1 subtype that directly binds to Programmed Death-Ligand 1 (PD-L1) and blocks its interactions with the Programmed Death-1 (PD-1) and B7.1 receptors. The primary objectives of this study are to assess the safety, tolerability and efficacy of CK-301 when administered intravenously as a single agent to subjects with selected recurrent or metastatic cancers.

Conditions

  • Lung Neoplasms
  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma, Small Cell
  • Malignant Mesothelioma, Advanced
  • Head and Neck Cancer
  • Melanoma
  • Merkel Cell Carcinoma
  • Renal Cell Carcinoma
  • Urothelial Carcinoma
  • Classical Hodgkin Lymphoma
  • Cutaneous Squamous Cell Carcinoma
  • Non Hodgkin Lymphoma
  • Endometrial Cancer

Interventions

  • CK-301 (cosibelimab)Drug

    CK-301 will be administered in periods of 28-day cycles.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Limiting ToxicityTime frame: Up to 4 weeks
  2. Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.03 (or most current version)Time frame: Screening through 4 weeks after study completion, an average of 6 months
  3. Confirmed Objective Response Rate (ORR) as per Response Evaluation Criteria in Solid Tumors (RECIST Version 1.1)Time frame: Part 2 Only: Average of 6 months

Locations

48 sites in 9 countries. Site status is shown where the registry gives one.

  • Research Site

    Wollongong, New South Wales, Australia

  • Research Site

    Benowa, Queensland, Australia

  • Research Site

    Buderim, Queensland, Australia

  • Research Site

    Greenslopes, Queensland, Australia

  • Research Site

    South Brisbane, Queensland, Australia

  • Research Site

    Woolloongabba, Queensland, Australia

  • Research Site

    Box Hill, Victoria, Australia

  • Research Site

    Malvern, Victoria, Australia

  • Research Site

    Besançon, France

  • Research Site

    Bordeaux, France

  • Research Site

    Grenoble, France

  • Research Site

    Lyon, France

  • Research Site

    Nice, France

  • Research Site

    Christchurch, New Zealand

  • Research Site

    Krakow, Poland

  • Research Site

    Lodz, Poland

  • Research Site

    Lublin, Poland

  • Research Site

    Poznan, Poland

  • Research Site

    Warsaw, Poland

  • Research Site

    Chelyabinsk, Russia

  • Research Site

    Kazan', Russia

  • Research Site

    Murmansk, Russia

  • Research Site

    Novosibirsk, Russia

  • Research Site

    Omsk, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Saint Petersburg, Russia

  • Research Site

    Tyumen, Russia

  • Research Site

    Volgograd, Russia

  • Research Site

    Cape Town, South Africa

  • Research Site

    George, South Africa

  • Research Site

    Port Elizabeth, South Africa

  • Research Site

    Pretoria, South Africa

  • Research Site

    Soweto, South Africa

  • Research Site

    Barcelona, Spain

  • Research Site

    Madrid, Spain

  • Research Site

    Málaga, Spain

  • Research Site

    Pamplona, Spain

  • Research Site

    San Cristóbal de La Laguna, Spain

  • Research Site

    Seville, Spain

  • Research Site

    Valencia, Spain

Showing 40 of 48 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.